Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Q2 2025 Earnings Call Transcript July 31, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $1.46, expectations were $1.07. Operator: Good day, and welcome to the ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...

Trump demanded that pharmaceutical companies lower their drug prices. But it's unclear how the government may enforce the ...

Bristol Myers Squibb reported unexpectedly strong second-quarter results, driven by legacy products like Eliquis, despite ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Bristol Myers Squibb (NYSE: BMY) has posted better-than-expected second-quarter 2025 results, driven by strong sales of its ...

Bristol Myers Squibb outperformed expectations in the second quarter, with boosted sales from key brands Eliquis, Opdivo, and ...